Life Science Investing Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Life Science Investing Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
Life Science Investing Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Life Science Investing Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Life Science Investing Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Life Science Investing Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
Life Science Investing Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
life science investing RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum-mRNA Cancer Vaccine Program Begins
life science investing Defence Breakthrough: Successfully Engineered Accum-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum-mRNA Cancer Vaccine Program Begins
life science investing Defence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute
life science investing Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million
